Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24872
Abstract: Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5‐FU 2400 mg/m2 × 48 h IV, peg‐filgrastim 6 mg SQ day 3, every 14 days) has substantial… read more here.
Keywords: systemic therapy; resectable pancreatic; primary systemic; mfolfirinox ... See more keywords
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0812
Abstract: Background Data analysis of specimens from prior clinical trials identified the immune co-simulatory molecule CD137 within the tumor microenvironment(TME) of pancreatic ductal adenocarcinoma(PDAC) that remain to be activated following vaccine induced T cell and PD-1… read more here.
Keywords: cd137 agonist; trial; anti cd137; neoadjuvant adjuvant ... See more keywords
Propensity score matched analysis of neoadjuvant therapy for resectable pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.381
Abstract: 381Background: Neoadjuvant therapy (NT) for resectable pancreatic cancer continues to be debated. There is little data to demonstrate survival benefit over patients who were treated with up front surgery (UFS) vs NT. We sought to… read more here.
Keywords: resectable pancreatic; pancreatic cancer; propensity score; neoadjuvant therapy ... See more keywords
Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.912153
Abstract: Background: Evidence of osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC) are currently lacking. This case series study aimed to assess the safety and feasibility of neoadjuvant osimertinib therapy followed by surgery… read more here.
Keywords: resectable non; neoadjuvant therapy; non small; therapy resectable ... See more keywords
Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v14.i10.1903
Abstract: Currently, 15 randomized controlled trials (RCTs) have been designed to investigate whether neoadjuvant therapy (NAT) benefits patients with resectable pancreatic adenocarcinoma (R-PA) compared to surgery alone. Five of them have acquired results so far; however,… read more here.
Keywords: neoadjuvant therapy; resectable pancreatic; cancer promising; pancreatic cancer ... See more keywords